Dublin, Jan. 26, 2017 -- Research and Markets has announced the addition of the "Implantable Infusion Pumps Market Analysis & Trends- Application (Cancer Treatment, Cancer Pain, Noncancer Pain, Spasticity, Analgesia, Mixed Sarcoma and Skin Cancers, Gastric Cancer and Diabetes Mellitus) - Forecast to 2025" report to their offering.
The Global Implantable Infusion Pumps Market is poised to grow at a CAGR of around 6.3% over the next decade to reach approximately $14.33 billion by 2025.
Some of the prominent trends that the market is Chemotherapy for cancer patients, Surge for near-physiologic programmable method of insulin delivery, Increase in device based drug delivery technologies and Growth Opportunities/Investment Opportunities.
Based on Application the market is categorized into Cancer Treatment, Spasticity, Analgesia and Diabetes Mellitus. The Cancer Treatment segment is further divided as Cancer Pain, Noncancer Pain, Mixed Sarcoma and Skin Cancers and Gastric Cancer.
This industry report analyzes the global markets for Implantable Infusion Pumps across all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2013, 2014 revenue estimations are presented for 2015 and forecasts from 2016 till 2025.
The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the world the report is a valuable asset for the existing players, new entrants and the future investors.
Key Topics Covered:
1 Market Outline
2 Executive Summary
3 Market Overview
3.1 Current Trends
3.1.1 Chemotherapy for cancer patients
3.1.2 Surge for near-physiologic programmable method of insulin delivery
3.1.3 Increase in device based drug delivery technologies
3.1.4 Growth Opportunities/Investment Opportunities
3.2 Drivers
3.3 Constraints
3.4 Industry Attractiveness
4 Implantable Infusion Pumps Market, By Application
4.1 Cancer Treatment
4.1.1.1 Cancer Pain
4.1.1.2 Noncancer Pain
4.1.1.3 Mixed Sarcoma and Skin Cancers
4.1.1.4 Gastric Cancer
4.2 Spasticity
4.3 Analgesia
4.4 Diabetes Mellitus
5 Implantable Infusion Pumps Market, By Geography
6 Key Player Activities
6.1 Acquisitions & Mergers
6.2 Agreements, Partnerships, Collaborations and Joint Ventures
6.3 Product Launch & Expansions
6.4 Other Activities
7 Leading Companies
7.1 Alnylam Pharmaceuticals, Inc.
7.2 Debiotech S.A.
7.3 Delpor, Inc.
7.4 Eksigent Technologies, LLC
7.5 Eli Lilly and Company
7.6 Flowonix Medical, Inc.
7.7 FluidSynchrony, LLC
7.8 Intarcia Therapeutics, Inc.
7.9 Medallion Therapeutics, Inc.
7.10 Nano Precision Medical
7.11 Pharmaco-Kinesis Corporation
7.12 University of Southern California Company
7.13 Halyard Health
7.14 Codman & Shurtleff
For more information about this report visit http://www.researchandmarkets.com/research/sm2s9p/implantable
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infusions and Injectables , Needles and Syringes , Endocrinology , Dermatological Drugs


Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand
Apple Turns 50: From Garage Startup to AI Crossroads
Britain Courts Anthropic Amid US Defense Department Dispute
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 



